Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment

Konstantina Dimitrakopoulou, Georgios N. Dimitrakopoulos, Kyriakos N. Sgarbas, Anastasios Bezerianos

Research output: Contribution to journalArticle

Abstract

Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an "integromics" network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.

Original languageEnglish (US)
Pages (from-to)15-33
Number of pages19
JournalOMICS A Journal of Integrative Biology
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Precision Medicine
Oncology
Tamoxifen
Medicine
Breast Neoplasms
Pharmacological Biomarkers
Therapeutics
Pharmacology
Health Planning
Clinical Pharmacology
Pharmacogenetics
Biomarkers
Proteasome Endopeptidase Complex
Transcriptome
Estrogen Receptors
Dynamic response
Time series
Cell Cycle
Transcription Factors
Cells

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Tamoxifen integromics and personalized medicine : Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment. / Dimitrakopoulou, Konstantina; Dimitrakopoulos, Georgios N.; Sgarbas, Kyriakos N.; Bezerianos, Anastasios.

In: OMICS A Journal of Integrative Biology, Vol. 18, No. 1, 01.01.2014, p. 15-33.

Research output: Contribution to journalArticle

Dimitrakopoulou, Konstantina ; Dimitrakopoulos, Georgios N. ; Sgarbas, Kyriakos N. ; Bezerianos, Anastasios. / Tamoxifen integromics and personalized medicine : Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment. In: OMICS A Journal of Integrative Biology. 2014 ; Vol. 18, No. 1. pp. 15-33.
@article{78d8ff8884f7469da804d44fe1a8607b,
title = "Tamoxifen integromics and personalized medicine: Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment",
abstract = "Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an {"}integromics{"} network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.",
author = "Konstantina Dimitrakopoulou and Dimitrakopoulos, {Georgios N.} and Sgarbas, {Kyriakos N.} and Anastasios Bezerianos",
year = "2014",
month = "1",
day = "1",
doi = "10.1089/omi.2013.0055",
language = "English (US)",
volume = "18",
pages = "15--33",
journal = "OMICS A Journal of Integrative Biology",
issn = "1536-2310",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Tamoxifen integromics and personalized medicine

T2 - Dynamic modular transformations underpinning response to tamoxifen in breast cancer treatment

AU - Dimitrakopoulou, Konstantina

AU - Dimitrakopoulos, Georgios N.

AU - Sgarbas, Kyriakos N.

AU - Bezerianos, Anastasios

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an "integromics" network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.

AB - Recent advances in pharmacogenomics technologies allow bold steps to be taken towards personalized medicine, more accurate health planning, and personalized drug development. In this framework, systems pharmacology network-based approaches offer an appealing way for integrating multi-omics data and set the basis for defining systems-level drug response biomarkers. On the road to individualized tamoxifen treatment in estrogen receptor-positive breast cancer patients, we examine the dynamics of the attendant pharmacological response mechanisms. By means of an "integromics" network approach, we assessed the tamoxifen effect through the way the high-order organization of interactome (i.e., the modules) is perturbed. To accomplish that, first we integrated the time series transcriptome data with the human protein interaction data, and second, an efficient module-detecting algorithm was applied onto the composite graphs. Our findings show that tamoxifen induces severe modular transformations on specific areas of the interactome. Our modular biomarkers in response to tamoxifen attest to the immunomodulatory role of tamoxifen, and further reveal that it deregulates cell cycle and apoptosis pathways, while coordinating the proteasome and basal transcription factors. To the best of our knowledge, this is the first report that informs the fields of personalized medicine and clinical pharmacology about the actual dynamic interactome response to tamoxifen administration.

UR - http://www.scopus.com/inward/record.url?scp=84893041759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893041759&partnerID=8YFLogxK

U2 - 10.1089/omi.2013.0055

DO - 10.1089/omi.2013.0055

M3 - Article

C2 - 24299457

AN - SCOPUS:84893041759

VL - 18

SP - 15

EP - 33

JO - OMICS A Journal of Integrative Biology

JF - OMICS A Journal of Integrative Biology

SN - 1536-2310

IS - 1

ER -